# Llusern Scientific

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/llusern-scientific

- Industry: Biotechnology
- Headquarters: Cardiff, UK
- Website: www.llusern.co.uk
- Total disclosed funding: $1.9M
- Latest round: Seed (Oct 14, 2024)
- Investors on record: 1

## About

Founded in 2020 and based in Cardiff, UK, Llusern Scientific Limited operates as a provider of molecular diagnostic devices to recognize viral and bacterial illnesses. The company was founded by its CEO, Emma Hayhurst, and CSO, Jeroen Nieuwland. In October 2024, Llusern Scientific Limited raised EUR 1.7 million in seed funding from the Development Bank of Wales.

Llusern Scientific specializes in rapid near-patient molecular diagnostics aimed at detecting bacterial and viral infections, with a primary focus on their product, the Lodestar DX molecular testing platform. This platform enables healthcare providers to perform UTI tests directly from urine samples. The Lodestar DX UTI test panels identify six specific pathogens. The company targets a diverse client base that includes healthcare facilities, veterinary practices, and direct consumers across various geographical markets, including the United Kingdom, Europe, and the United States.

The company plans to utilize the October 2024 funding raised to expand its urinary tract infection diagnostics.

## Funding rounds

- Seed, Oct 14, 2024, $1.9M — Development Bank of Wales

## Investors

- Development Bank of Wales (https://capitalatlas.ai/funds/development-bank-of-wales) — Seed